Objectives: SAV1 is a human homologue of Salvador that contains two protein-protein interaction modules known as WW domains and acts as a scaffolding protein. SAV1
profiling of colorectal cancer has become increasingly important for identification of prognostic and predictive biomarkers, as well as for insights into the biology that drives the tumour.
3,4 DNA, proteins, messenger RNA and micro-RNA have all been evaluated in the development of colorectal cancer. 3 However, the mechanisms underlying the development of colorectal cancer are still not fully understood. Novel therapeutic targets remain to identify.
The Salvador family WW domain-containing 1 (SAV1, also known as WW45) is a WW domain-containing protein. This protein contains two WW domains and a coiled-coil region. SAV1 belongs to the core kinase components of Hippo signalling pathway. 5 The transcriptional co-activators YAP1 and TAZ are the downstream effectors of the SAV1 and regulate target gene expression. SAV1 promotes the phosphorylation of YAP and inactivates it by cooperating with the other core kinase components, including MOB, MST1/2 and LATS1/2.
6,7
SAV1 contributes to establishing a polarized cell structure in addition to regulating proliferation. 8 In murine renal tubules, deficiency of Sav1 causes structural and cellular abnormalities of the epithelial cells, including significant enlargement of their nuclei through inactivation of the Hippo pathway. 9 In addition, SAV1-MST2-NEK2A
and Eg5 have distinct, but complementary functions, in centrosome disjunction. 10 Accumulating evidence show that SAV1 participates in the development of diverse types of cancer. In mucinous tubular and spindle cell carcinoma, SAV1 is involved in a mutually exclusive fashion. 11 In patients with pancreatic ductal adenocarcinoma (PDAC), the SAV1 expression is reduced and SAV1 is a potential prognostic marker and target for PDAC therapy. 12 In human hepatocellular carcinoma, inactivation of SAV1 is significantly associated with poor prognosis. 13 In addition, down-regulation of SAV1 plays a role in the pathogenesis of high-grade clear cell renal cell carci-
noma.
14 However, the roles of SAV1 in other types of cancer remain unknown.
Here we aimed to study the roles of SAV1 in human colorectal cancer and the underlying mechanism. We show that SAV1 expression is down-regulated in human colorectal cancer. SAV1 inhibits the growth of colorectal cancer cells in vitro and in vivo. Mechanism study reveals that SAV1 inhibits YAP to repress the activation of AktmTOR signalling, which contributes to the anti-cancer function of SAV1.
| MATERIALS AND METHODS

| Patient tissues
Twelve colorectal cancer patients with full information were involved University. The information of patients is shown in Table 1 .
| Cell lines and culture
The colorectal cancer cell lines DLD-1, HCT1116, SW480, Caco-2 and HT-29 were purchased from ATCC. HEK293FT cells were purchased from Thermo. The colorectal cancer cell lines and HEK293FT cells were cultured in advanced DMEM medium (Thermo, #12491-015) supplied with 10% foetal bovine serum (Thermo, #12484-010) and penicillin-streptomycin (Thermo, #15140163).
| Perpetration of lentivirus and transduction
The ViraPower ™ II Lentiviral Gateway ® Expression System was purchased from Thermo (#K36720 Forty-eight hours later, the infected cells were then selected for additional 72 hours with puromycin.
| Western blot
Fresh tissues from patients, tumour tissues from nude mice and cultured cells were subjected to protein extraction with RIPA (Beyotime, #P0013B) supplied with proteinase inhibitor cocktail (Promega, #G6521). Western blot was performed as described previously. 15 The following primary antibodies were used: anti-SAV1 
| Quantitative real-time PCR
Total RNA was extracted from fresh tissues and cells by using the TRIzol reagent (Thermo, #10296010 SAV1 forward: 5′-ATGCTGTCCCGAAAGAAAACC-3′
SAV1 reverse: 5′-AGGCATAAGATTCCGAAGCAGA-3′
GAPDH forward: 5′-TGTGGGCATCAATGGATTTGG-3′
GAPDH reverse: 5′-ACACCATGTATTCCGGGTCAAT-3′
| Measurement of cell number
The number of colorectal cancer cells was monitored by Cell Counting Kit-8 kit (Sigma, #96992) to evaluate the growth rate of cells in vitro.
| Colony formation assay
Transduced DLD-1 and HT-29 cells were subjected to colony formation assay as described previously. 
| Statistical analysis
All the values are expressed and mean±SEM of at least three independent experiments if no other statement is provided. Normality tests were assessed via the Shapiro-Wilk test. The difference between two groups was analysed by paired or unpaired Student's t-test when the data matched the standard. One-way ANOVA analysis followed
by Bonferroni post hoc test was applied for analysing the difference among groups more than three when the data matched the standard.
All the statistical analysis was carried out by using the spss 20. version.
| RESULTS
| SAV1 is down-regulated in human colorectal cancer tissues
The roles of the SAV1 protein in human colorectal cancer remain unknown. In this study, we aimed to investigate the potential func- 
| SAV1 inhibits the growth of colorectal cancer in vitro
As To further evaluate whether overexpression of SAV1 protein could repress the development of colorectal cancer, we overexpressed SAV1 protein in DLD-1 and HT-29 cell with lentivirus ( Figure 2D ). We found that SAV1 overexpression in colorectal cancer cells decreased their growth rate and repressed the capacity of colony formation ( Figure 2E,F) .
Taken together, these in vitro findings demonstrated that SAV1
could inhibit the growth and colony formation of colorectal cancer cells.
| SAV1 inhibits the growth of colon cancer in vivo
We were still very interested whether SAV1 could regulate cancer cell growth in vivo. Therefore, we subjected the DLD-1 cells with a stable SAV1 knockdown to in vivo tumour growth assay by performing F I G U R E 3 SAV1 inhibits the growth of colorectal cancer cells in vivo. A, The curve of the tumour growth in vivo. DLD-1 cells with/without stable SAV1 knockdown were subjected to tumour growth assay in vivo. The volume of tumours was monitored every 3 days. The data were analysed by one-way ANOVA. *P<.05, **P<.01, ***P<.001 vs sh-Ctrl at the same time point. n=10 in each group. B, Representative image showing tumour size. DLD-1 cells with/without stable SAV1 knockdown were subjected to tumour growth assay in vivo. The tumours were harvested at the end of the experiment, and the image was captured. C, Tumour weight of colon cancer. DLD-1 cells with/without stable SAV1 knockdown were subjected to tumour growth assay in vivo. The tumours were harvested at the end of the experiment, and tumour weight was evaluated. The data were analysed by unpaired Student's t-test. ***P<.001. n=10 in each group. D, The curve of the tumour growth in vivo. DLD-1 cells with/without stable SAV1 overexpression were subjected to tumour growth assay in vivo. The volume of tumours was monitored every 3 days. The data were analysed by one-way ANOVA. ***P<.001 vs Ctrl at the same time point. n=10 in each group. E, Representative image showing tumour size. DLD-1 cells with/without stable SAV1 overexpression were subjected to tumour growth assay in vivo. The tumours were harvested at the end of the experiment, and the image was captured. F, Tumour weight of colon cancer. DLD-1 cells with/without stable SAV1 overexpression were subjected to tumour growth assay in vivo. The tumours were harvested at the end of the experiment, and tumour weight was evaluated. The data were analysed by unpaired Student's t-test. ***P<.001. n=10 in each group xenograft experiment in nude mice. We monitored the tumour size for 4 weeks and found that SAV1 knockdown significantly increased the tumour size from the day 21 compared with the control group ( Figure 3A ). In addition, the tumour size was larger in the SAV1 knockdown group compared with the control group at the end of the experiment ( Figure 3B ). We also calculated the weight of tumours at the end of experiments, and the results showed that the tumour weight of SAV1 knockdown group was much larger than that of the control group ( Figure 3C ). Therefore, SAV1 knockdown promoted the growth of colorectal cancer cells in vivo.
We also investigated whether overexpression of SAV1 could inhibit the development of colorectal cancer in vivo. As thus, DLD-1 cells with or without SAV1 stable overexpression were subjected to in vivo tumour growth assay. We found that SAV1 overexpression repressed the in vivo growth of DLD-1 cells from the day 21 ( Figure 3D ). In addition, the tumour size in SAV1 overexpression group was smaller than that of the control group at the end of the experiments ( Figure 3E ). In addition, the average tumour weight was also decreased by overexpressing SAV1 ( Figure 3F ). Similarly, SAV1 knockdown repressed the in vivo growth rate and final tumour weight of HT-29 cells (Supplementary Figure S2A,B) . Therefore, SAV1 overexpression repressed the growth of colorectal cancer cells in vivo.
Taken together, our in vitro and in vivo evidence showed that SAV1
inhabited the development of colorectal cancer.
| SAV1 represses Akt-mTOR pathway in colorectal cancer
The next question we wanted to answer is how SAV1 inhibits the development of colorectal cancer. The Akt-mTOR signalling pathway is a core mechanism underlying colorectal cancer development. 16 ,17 Therefore, we analysed the potential effects of SAV1 on Akt-mTOR signalling. Indeed, we observed that the phosphorylation levels of Akt, mTOR and S6K1 were up-regulated in colorectal cancer tissues compared with non-cancer colon tissues ( Figure 4A ,B).
We also analysed the activation of the Akt-mTOR signalling pathway in tumours obtained from nude mice. Consistently, when SAV1 was knocked down, the phosphorylation levels of Akt, mTOR and S6K1 Therefore, we also determined whether SAV1 regulates the phosphorylation levels of glycogen synthase kinase 3 beta (GSK3β) and β-catenin, two compartments of the Wnt/β-catenin pathway. The results showed that SAV1 knockdown did not alter the phosphorylation levels of GSK3β and β-catenin (Supplementary Figure S3) , indicating that SAV1 was unable to change the Wnt/β-catenin signalling.
To further confirm whether activation of the mTOR signalling accounts for SAV1-mediated effects on colorectal cancer, we inhibited mTOR with rapamycin. Rapamycin treatment repressed the phosphorylation of S6K1 and blocked the activation of S6K1 by SAV1 knockdown in DLD-1 cells ( Figure 5A ). Inhibition of mTOR with rapamycin reduced the growth rate of DLD-1 cells, and SAV1 knockdown was unable to promote the growth of DLD-1 cells in the presence of rapamycin ( Figure 5B ). In addition, we observed that rapamycin treatment reduced the numbers of DLD-1 colonies and blocked the effects of SAV1 on colony formation of DLD-1 cells ( Figure 5C ). Therefore, the mTOR signalling is important for SAV1-mediated effects on colorectal cancer cells in vitro. To further validate this finding in vivo, the tumour-bearing nude mice were treated with rapamycin at the dose of 5 mg/kg/day. The results showed that rapamycin treatment reduced the tumour weight (DLD-1 cells) in vivo, and knockdown of SAV1 was unable to promote in vivo growth of DLD-1 cells when mTOR was inhibited by rapamycin ( Figure 5D ).
Taken together, our findings demonstrated that SAV1 repressed Akt-mTOR signalling pathway to inhibit the development of colorectal cancer.
| The inhibition of Akt-mTOR by SAV1 is mediated by YAP
Finally, we investigated how SAV1 represses the activation of AktmTOR signalling. The YAP is a classic downstream of SAV1. 19 SAV1
could promote the phosphorylation of YAP and repress its activation.
5
Indeed, we observed that the phosphorylation level of YAP was decreased by SAV1 knockdown and increased by SAV1 overexpression in DLD-1 cells ( Figure 6A ). YAP is an activator of Akt-mTOR signalling by promoting the expression of miR-29 and inhibition of PTEN. 19 We knocked down the expression of YAP and investigated its contribution to SAV1-mediated inhibition of Akt-mTOR signalling. Knockdown of YAP reduced the phosphorylation of Akt, mTOR and S6K1 in DLD-1 cells ( Figure 6B ). Interestingly, SAV1 knockdown was unable to activate the Akt-mTOR signalling when YAP was deficient ( Figure 6B ). 
| DISCUSSION
In the present work, we provide evidence that SAV1 is a tumour suppres- The functions of SAV1 in several types of cancer have been reported. In breast cancer, SAV1 expression was down-regulated in breast cancer samples compared to normal breast tissues. 20 In human PDAC, lower expression of SAV1 is involved in the progression of PDAC, suggesting that SAV1 may be a potential prognostic marker and target for PDAC therapy. 12 Additionally, SAV1 is frequently downregulated in high-grade clear cell renal cell carcinoma. 14 In this study,
we also found that the mRNA and protein levels of SAV1 were significantly down-regulated in human colorectal cancer tissues compared with adjacent non-cancer tissues. These findings implicate that downregulation of SAV1 is involved in diverse cancers, and may be a core mechanism for these cancers. However, the diagnostic and prognostic values of SAV1 in human colorectal cancer remain to elucidate. 23 showed that increased prostaglandin E2 (PGE2) and dysregulation of Hippo pathway cooperates to induce colon cancer development. Therefore, it is also interesting to investigate the potential cooperation between SAV1 and PGE2 in colorectal cancer.
Overexpression of YAP/TAZ is an independent predictor of prognosis in colorectal cancer. 7 In addition, we found that SAV1 repressed the activation of Akt-mTOR in a YAP-dependent manner, and phos- we identify SAV1 as a tumour suppressor in human colorectal cancer.
SAV1 represses the growth of colorectal cancer cells by inactivating
Akt-mTOR signalling in a YAP-dependent manner. Therefore, SAV1
may serve as a potential target for treatment of human colorectal cancer.
